Literature DB >> 14511463

Intracellular staining for HIV-specific IFN-gamma production: statistical analyses establish reproducibility and criteria for distinguishing positive responses.

Wendy L Trigona1, James H Clair, Natasha Persaud, Kara Punt, Margaret Bachinsky, Usha Sadasivan-Nair, Sheri Dubey, Lynda Tussey, Tong-Ming Fu, John Shiver.   

Abstract

The cellular immune response plays a pivotal role in controlling the spread of HIV-1 infection by lysing virally infected cells and producing potent antiviral cytokines, such as interferon-gamma (IFN-gamma). Flow cytometric methods have been established to evaluate the contribution of both CD4 and CD8 subsets of T lymphocytes to the immune response to HIV by measuring their production of intracellular IFN-gamma following brief antigenic stimulation. We present a statistical treatment of intracellular cytokine staining (ICS) data that is aimed at establishing the reproducibility and robustness of this assay for use in HIV clinical trials. Comparisons of responses from HIV-seronegative and seropositive individuals were used to establish a 2-fold criterion for distinguishing positive responses with a low probability of false positives (<1%). Additional comparisons established that the reproducibility of the assay is between 1.4 and 2.0-fold depending on the magnitude of the response. Little variability was demonstrated between multiple operators for both the execution and analysis components of these experiments (<10% difference with 95% confidence). We conclude that the statistical criteria established by these analyses allow for the accurate detection and comparison of positive responses. Using these statistical criteria, the ICS assay is sufficiently robust for use in HIV-specific vaccine trials.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14511463     DOI: 10.1089/107999003322226023

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  11 in total

1.  Mixture models for single-cell assays with applications to vaccine studies.

Authors:  Greg Finak; Andrew McDavid; Pratip Chattopadhyay; Maria Dominguez; Steve De Rosa; Mario Roederer; Raphael Gottardo
Journal:  Biostatistics       Date:  2013-07-24       Impact factor: 5.899

2.  COMPASS identifies T-cell subsets correlated with clinical outcomes.

Authors:  Lin Lin; Greg Finak; Kevin Ushey; Chetan Seshadri; Thomas R Hawn; Nicole Frahm; Thomas J Scriba; Hassan Mahomed; Willem Hanekom; Pierre-Alexandre Bart; Giuseppe Pantaleo; Georgia D Tomaras; Supachai Rerks-Ngarm; Jaranit Kaewkungwal; Sorachai Nitayaphan; Punnee Pitisuttithum; Nelson L Michael; Jerome H Kim; Merlin L Robb; Robert J O'Connell; Nicos Karasavvas; Peter Gilbert; Stephen C De Rosa; M Juliana McElrath; Raphael Gottardo
Journal:  Nat Biotechnol       Date:  2015-05-25       Impact factor: 54.908

3.  Comparative immunogenicity of human immunodeficiency virus particles and corresponding polypeptides in a DNA vaccine.

Authors:  Wataru Akahata; Zhi-yong Yang; Gary J Nabel
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

4.  Relationship of HIV reservoir characteristics with immune status and viral rebound kinetics in an HIV therapeutic vaccine study.

Authors:  Jonathan Z Li; Andrea Heisey; Hayat Ahmed; Hongying Wang; Lu Zheng; Mary Carrington; Terri Wrin; Robert T Schooley; Michael M Lederman; Daniel R Kuritzkes
Journal:  AIDS       Date:  2014-11-28       Impact factor: 4.177

5.  High-throughput flow cytometry data normalization for clinical trials.

Authors:  Greg Finak; Wenxin Jiang; Kevin Krouse; Chungwen Wei; Ignacio Sanz; Deborah Phippard; Adam Asare; Stephen C De Rosa; Steve Self; Raphael Gottardo
Journal:  Cytometry A       Date:  2013-12-31       Impact factor: 4.355

6.  Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial.

Authors:  Jonathan Z Li; Zabrina L Brumme; Chanson J Brumme; Hongying Wang; John Spritzler; Michael N Robertson; Michael M Lederman; Mary Carrington; Bruce D Walker; Robert T Schooley; Daniel R Kuritzkes
Journal:  J Infect Dis       Date:  2011-04-01       Impact factor: 5.226

7.  AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein.

Authors:  Robert T Schooley; John Spritzler; Hongying Wang; Michael M Lederman; Diane Havlir; Daniel R Kuritzkes; Richard Pollard; Cathy Battaglia; Michael Robertson; Devan Mehrotra; Danilo Casimiro; Kara Cox; Barbara Schock
Journal:  J Infect Dis       Date:  2010-09-01       Impact factor: 5.226

8.  Peptide impurities in commercial synthetic peptides and their implications for vaccine trial assessment.

Authors:  Jeffrey R Currier; Lynee M Galley; Holger Wenschuh; Vivian Morafo; Silvia Ratto-Kim; Clive M Gray; Leonard Maboko; Michael Hoelscher; Mary A Marovich; Josephine H Cox
Journal:  Clin Vaccine Immunol       Date:  2007-12-12

9.  Characteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic HIV-1 gag vaccine trial.

Authors:  Jonathan Z Li; Chanson J Brumme; Michael M Lederman; Zabrina L Brumme; Hongying Wang; John Spritzler; Mary Carrington; Kathleen Medvik; Bruce D Walker; Robert T Schooley; Daniel R Kuritzkes
Journal:  PLoS One       Date:  2012-03-30       Impact factor: 3.240

10.  Use of RT-defective HIV virions: new tool to evaluate specific response in chronic asymptomatic HIV-infected individuals.

Authors:  Alberto Crespo Guardo; Carmen Alvarez-Fernández; Hodei Arberas; Javier García-Pérez; Felipe García; Manuel Enric Bargalló; María José Maleno; José María Gatell; Beatriz Mothe; José Alcami; Sonsoles Sánchez-Palomino; Montserrat Plana
Journal:  PLoS One       Date:  2013-03-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.